Eileen O'Reilly

Eileen O'Reilly is a pancreatic cancer specialist at Memorial Sloan Kettering who leads clinical trials examining neoadjuvant strategies for borderline resectable PDAC and novel adjuvant therapies including ctDNA-guided approaches. Her translational research program investigates KRAS ctDNA as a marker of minimal residual disease after resection and adjuvant treatment response. She contributed to investigations of nab-paclitaxel plus gemcitabine and novel targeted agents in resected PDAC. O'Reilly is a prolific author and investigator in pancreatic cancer clinical research with international recognition.